Data layers Raw facts Calculated Model prediction AI interpretation

Company Overview

Stock NameBasecare-B
Stock Code02170
Company Full NameTo be extracted
IndustryHealthcare
Principal Activities中國輔助生殖基因檢測解決方案的創新平台,提供PGT-A試劑盒等植入前基因檢測產品,並開發PGT-M、PGT-SR、CNV、WES試劑盒及基因檢測設備儀器,為醫院和生殖診所提供一站式定制化綜合解決方案。
Listing Date2021-02-08
Listing Rules EraOld Rules
Listing Rules Chapter18A生物科技
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)中國江蘇省蘇州市蘇州工業園區星湖街218號生物納米園A3樓101室
Business Address (Hong Kong)香港灣仔皇后大道東248號陽光中心40樓
Place of IncorporationTo be extracted
Listing MethodTo be extracted
Listing BoardMain Board
Websitebasecare.cn
Share Registrar香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited)
Registrar Contact(852)2862 8628
A-Share/US Dual ListingNo

Offering Information

Offering Mechanism Mechanism A
Offer PriceHK$ 27.36 / shares
Offer Price RangeFinal offer price only, no range
Lot Size500 shares
Entry ThresholdHK$ 13,680
Par ValueRMB 1.0 / shares
Offer Period2021-01-27 to 2021-02-01
Global Offering Shares66,667,000 shares
HK Public Offer Shares (Initial)6,667,000 shares (10.0%)
Public Offer Lots (Initial)13,334lots (Pool A6,667lots,Pool B6,667lots)
International Placing Shares (Initial)60,000,000 shares (90.0%)
Offer Ratio~10.0%
Total Shares Post-IPO266,667,000 shares
Greenshoe (Over-allotment Option)Yes
Stabilizing Manager (Greenshoe)To be extracted
Cornerstone Share38.3%
Clawback TiersTo be extracted
Reallocation OptionYes
Total Global Offering SizeHK$ 1,824,009,120

Subscription Tiers

Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.

Pool A
Lots SubscribedShares SubscribedSubscription Amount (HKD)
1 lots 500 HK$ 13,680
2 lots 1,000 HK$ 27,360
3 lots 1,500 HK$ 41,040
4 lots 2,000 HK$ 54,720
5 lots 2,500 HK$ 68,400
6 lots 3,000 HK$ 82,080
7 lots 3,500 HK$ 95,760
8 lots 4,000 HK$ 109,440
9 lots 4,500 HK$ 123,120
10 lots 5,000 HK$ 136,800
12 lots 6,000 HK$ 164,160
14 lots 7,000 HK$ 191,520
16 lots 8,000 HK$ 218,880
18 lots 9,000 HK$ 246,240
20 lots 10,000 HK$ 273,600
30 lots 15,000 HK$ 410,400
40 lots 20,000 HK$ 547,200
50 lots 25,000 HK$ 684,000
60 lots 30,000 HK$ 820,800
70 lots 35,000 HK$ 957,600
80 lots 40,000 HK$ 1,094,400
90 lots 45,000 HK$ 1,231,200
100 lots 50,000 HK$ 1,368,000
120 lots 60,000 HK$ 1,641,600
140 lots 70,000 HK$ 1,915,200
160 lots 80,000 HK$ 2,188,800
180 lots 90,000 HK$ 2,462,400
200 lots 100,000 HK$ 2,736,000
300 lots 150,000 HK$ 4,104,000
Pool B
Lots SubscribedShares SubscribedSubscription Amount (HKD)
400 lots 200,000 HK$ 5,472,000
500 lots 250,000 HK$ 6,840,000
600 lots 300,000 HK$ 8,208,000
700 lots 350,000 HK$ 9,576,000
800 lots 400,000 HK$ 10,944,000
900 lots 450,000 HK$ 12,312,000
1,000 lots 500,000 HK$ 13,680,000
1,200 lots 600,000 HK$ 16,416,000
1,400 lots 700,000 HK$ 19,152,000
1,600 lots 800,000 HK$ 21,888,000
1,800 lots 900,000 HK$ 24,624,000
2,000 lots 1,000,000 HK$ 27,360,000
3,000 lots 1,500,000 HK$ 41,040,000
4,000 lots 2,000,000 HK$ 54,720,000
5,000 lots 2,500,000 HK$ 68,400,000
6,667 lots 3,333,500 HK$ 91,204,560

Stock Connect Inclusion Analysis

26Q4 Regular Review
Inclusion Pathway Regular Path
HK Market Cap HK$ 129.4M
Est. Threshold HK$ 9.39B
Analysis Result HK market cap below threshold, need +7157%

Valuation & Financials

Market Cap (at Offer Price)HK$ 7,296,009,120
H-Share Market Cap (at Offer Price)HK$ 2,026,676,076
Pre-IPO Valuation (Last Round)Not disclosed
P/E Ratio不适用(公司处于亏损状态)
Profit/Loss Status亏损人民币534.0百万元
Period-End Cash Balance人民币24.2百万元
Listing ExpensesTo be extracted
Listing Expenses / Funds RaisedTo be extracted
Total Pre-IPO InvestmentTo be extracted

Financial Data

Unit: '000 RMB
Income Statement
Item 20182019
Revenue 32,60955,685
Cost of sales -24,472-29,432
Gross profit 8,13726,253
Other income and gains, net 3,9993,958
Selling and distribution expenses -10,866-11,011
Administrative expenses -34,243-77,990
Operating profit -51,816-88,730
Net finance costs -927-11,316
Share of associates and JVs -174-776
Profit before tax -157,005-5,530,570
Income tax expense -5,069-22,290
Profit for the year -157,700-53,533,997
Profit attributable to owners -154,877-5,311,336
Income Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
First Day CloseHK$ 27.7
First Day OpenHK$ 30.0
First Day Change1.24%
First Day Volume50895400.0
First Day Turnover1543960000.0
Use of Proceeds
1、約30%或515.0百萬港元將分配予我們的核心產品PGT-A試劑盒; 2、約20%或343.3百萬港元將用于PGT-M試劑盒的臨床試驗、注冊申報及商業化; 3、約30%或515.0百萬港元將分配用于我們其他產品的開發、臨床試驗及注冊申報; 4、約10%或171.7百萬港元將用于提高我們的研發能力及提升我們的技術; 5、約10%或171.7百萬港元將用作我們的營運資本及一般企業用途。

Underwriting Syndicate

Sole Sponsor (1)
中信证券(香港)有限公司 CE AAK249
Overall Coordinators (3)
中信里昂证券有限公司 CE AAB893 Citigroup Global Markets Asia Limited CE AAA137 中国国际金融香港证券有限公司 CE AEN894
Joint Bookrunners (7)
中信里昂证券有限公司 CE AAB893 Citigroup Global Markets Asia Limited CE AAA137 中国国际金融香港证券有限公司 CE AEN894 海通国际证券有限公司 CE AAF806 招银国际融资有限公司 CE AVM940 ICBC INTERNATIONAL SECURITIES LIMITED CE ARO299 SPDB International Capital Limited CE BFZ375
Joint Lead Managers (8)
中信里昂证券有限公司 CE AAB893 Citigroup Global Markets Asia Limited CE AAA137 中国国际金融香港证券有限公司 CE AEN894 海通国际证券有限公司 CE AAF806 招银国际融资有限公司 CE AVM940 ICBC INTERNATIONAL SECURITIES LIMITED CE ARO299 SPDB International Capital Limited CE BFZ375 富途证券国际(香港)有限公司 CE AZT137

Cornerstone Investors

#Investor NameInvestment AmountShares Subscribed% of Offer Shares% of Total SharesLock-up PeriodEst. Unlock Date
1 Affin Hwang Asset Management Berhad 77,524,560 HKD — 4.30% — 6 months 2021-08-08
2 CRF Investment Holdings Company Limited 155,062,800 HKD — 8.50% — 6 months 2021-08-08
3 Foresight Orient Global Superior Choice SPC 38,755,440 HKD — 2.10% — 6 months 2021-08-08
4 Lake Bleu Prime Healthcare Master Fund Limited 155,062,800 HKD — 8.50% — 6 months 2021-08-08
5 OrbiMed Funds 155,062,800 HKD — 8.50% — 6 months 2021-08-08
6 WinTwin Capital Limited 77,524,560 HKD — 4.30% — 6 months 2021-08-08
7 常春藤资产管理(香港)有限公司 38,755,440 HKD — 2.10% — 6 months 2021-08-08

Directors & Management

PositionChinese nameEnglish Name
Chairman梁波—
Company Secretary戴靜、嚴洛鈞—
No director data available.

Major Shareholders

Major Shareholders & Holdings梁波直接及透過貝康投資合共持有約34.25%權益;貝康投資持有13.53%;高瓴香港持有H股5.11%(或內資股及未上市外資股3.96%);中誠方圓二期持有5.70%;元禾原點持有4.61%。
About this page

This page shows Basecare-B (02170) prospectus details: offer price range, fundraise size, cornerstone investors, greenshoe, Pool A/B allocation and syndicate. For eligible IPOs it also provides a Stock Connect inclusion analysis, indicating the pathway and estimated timing for Southbound Connect admission; for A-share / US secondary listings, it additionally compares the other market's price, exchange rate and the H-share premium/discount. Data is parsed from the HKEX prospectus and related announcements. New to IPO subscription? See Hong Kong IPO Subscription 101.

Cibo — HK IPO Allotment Forecasts, Allottee Profiling & Stock Connect